Sugi Predict

Sugi Predict / Compounds / SCHEMBL310378

SCHEMBL310378

SCHEMBL310378

COc1cc(N2CCC(N3CCOCC3)CC2)ccc1N

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.47
▸ LGMN Q99538 3/20 0.47
▸ TTK P33981 2/20 0.47
▸ CAMK2D Q13557 1/20 0.46
▸ ALK Q9UM73 6/20 0.45
▸ L3MBTL3 Q96JM7 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ INSR P06213 1/20 0.45
▸ IGF1R P08069 1/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ AOC3 Q16853 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ KIT P10721 1/20 0.43
▸ KDR P35968 1/20 0.43
▸ FLT3 P36888 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL519900 0.95 L3MBTL3 (0.48) CHEK1LGMNTTKCAMK2DALK
SCHEMBL520455 0.93 SMPD3 (0.44) CHEK1LGMNTTKCAMK2DALK
SCHEMBL1911911 0.90 L3MBTL3 (0.45) LGMNTTKCAMK2DALKL3MBTL3
SCHEMBL521235 0.90 CHEK1 (0.44) CHEK1LGMNIGF1RJAK2AOC3
SCHEMBL310594 0.90 TTK (0.41) CHEK1LGMNTTKCAMK2DALK
SCHEMBL10205071 0.89 L3MBTL3 (0.46) ALKL3MBTL3L3MBTL1INSRIGF1R
SCHEMBL13981451 0.88 L3MBTL3 (0.43) CHEK1LGMNALKL3MBTL3L3MBTL1
SCHEMBL10206202 0.88 L3MBTL3 (0.53) ALKL3MBTL3L3MBTL1INSRIGF1R
SCHEMBL520836 0.88 L3MBTL1 (0.57) ALKL3MBTL3L3MBTL1INSRIGF1R
SCHEMBL309548 0.87 L3MBTL1 (0.55) L3MBTL3L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110799190-B Heterocyclic compounds 卡都瑞恩医药有限公司 2024-04-19 — — CN disclosed
US-11897877-B2 Inhibitor compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-02-13 — — US disclosed
US-20230065740-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. 2023-03-02 — — US disclosed
US-20230048132-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. 2023-02-16 — — US disclosed
US-20220402912-A1 INHIBITOR COMPOUNDS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2022-12-22 — — US disclosed
US-20220402912-A1 INHIBITOR COMPOUNDS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2022-12-22 — — US disclosed
CN-114213400-B Thiophene-containing pyrimidine compound and preparation method and application thereof 贵州大学 2022-11-08 — — CN disclosed
CN-115260234-A 2-amino-4-amino aryl phospho-oxypyrimidine compound and preparation method and application thereof 江苏医药职业学院 2022-11-01 — — CN disclosed
US-20220220103-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. 2022-07-14 — — US disclosed
CN-114213400-A Thiophene-containing pyrimidine compound and preparation method and application thereof 贵州大学 2022-03-22 — — CN disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 — — EP disclosed
WO-2009020990-A1 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER SMITHKLINE BEECHAM CORPORATION (US) 2009-02-12 — — WO disclosed
WO-2009020990-A1 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER SMITHKLINE BEECHAM CORPORATION (US) 2009-02-12 — — WO disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 — — WO disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 — — WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 — — US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 — — US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 — — US disclosed
US-20080132504-A1 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2008-06-05 — — US disclosed
US-20080132504-A1 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2008-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402912-A1 INHIBITOR COMPOUNDS BUB1B, BUB1, CDK1 CHEK1 5/4885LGMN 4274/4885TTK 30/4885
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 CHEK1 240/4885LGMN 3434/4885TTK 159/4885
US-11897877-B2 Inhibitor compounds BUB1B, BUB1, CDK1 CHEK1 5/4885LGMN 4274/4885TTK 30/4885
US-20080132504-A1 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders TYMS, TYMP, DPYD CHEK1 659/4885LGMN 3964/4885TTK 3767/4885
US-20230065740-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK2, CDK1, CCNK CHEK1 59/4885LGMN 2924/4885TTK 67/4885
US-20220220103-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK2, CDK1, CCNK CHEK1 59/4885LGMN 2924/4885TTK 67/4885
US-20230048132-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK2, CDK1, CCNK CHEK1 59/4885LGMN 2924/4885TTK 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.